Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 15;188(10):2637-2655.e31.
doi: 10.1016/j.cell.2025.03.015. Epub 2025 Apr 9.

Engineered nucleocytosolic vehicles for loading of programmable editors

Affiliations
Free article

Engineered nucleocytosolic vehicles for loading of programmable editors

Julian Geilenkeuser et al. Cell. .
Free article

Abstract

Advanced gene editing methods have accelerated biomedical discovery and hold great therapeutic promise, but safe and efficient delivery of gene editors remains challenging. In this study, we present a virus-like particle (VLP) system featuring nucleocytosolic shuttling vehicles that retrieve pre-assembled Cas-effectors via aptamer-tagged guide RNAs. This approach ensures preferential loading of fully assembled editor ribonucleoproteins (RNPs) and enhances the efficacy of prime editing, base editing, trans-activators, and nuclease activity coupled to homology-directed repair in multiple immortalized, primary, stem cell, and stem-cell-derived cell types. We also achieve additional protection of inherently unstable prime editing guide RNAs (pegRNAs) by shielding the 3'-exposed end with Csy4/Cas6f, further enhancing editing performance. Furthermore, we identify a minimal set of packaging and budding modules that can serve as a platform for bottom-up engineering of enveloped delivery vehicles. Notably, our system demonstrates superior per-VLP editing efficiency in primary T lymphocytes and two mouse models of inherited retinal disease, highlighting its therapeutic potential.

Keywords: VLPs; base editing; cell therapy; gene delivery; gene therapy; genome editing; in vivo delivery; prime editing; virus-like particles.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests D.-J.J.T., J.G., N.A., and G.G.W. are inventors of the described technology and have filed patent applications through Helmholtz Munich and the Technical University of Munich (TUM). K.P. is a consultant for Polgenix Inc. and serves on the Scientific Advisory Board at Hyperion Eye Ltd. This work does not pertain to the above activities.

Substances

LinkOut - more resources